Moderna blows past expectations with $6.1B in revenue, mostly from COVID-19 vaccine

Biotech firm Moderna said on Wednesday that it tripled sales of its COVID-19 vaccine during the first three months of 2022 and smashed most analysts’ expectations with more than $6 billion in revenue.